Paclitaxel drug-eluting stents in peripheral arterial disease: a health technology assessment
Health Quality Ontario
Record ID 32016000197
English
Authors' recommendations:
Based on evidence of low to moderate quality, Zilver paclitaxel drug-eluting stents were associated with a higher patency rate than angioplasty or bare metal stents, and with fewer adverse events than angioplasty. The effectiveness and safety of Zilver paclitaxel drug-eluting stents and paclitaxel drug-coated balloons were similar.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.hqontario.ca/Portals/0/Documents/eds/ohtas/hta-drug-eluting-stent-en-1511.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Humans
- Peripheral Arterial Disease
- Drug-Eluting Stents
- Paclitaxel
- Sirolimus
- Technology Assessment, Biomedical
Contact
Organisation Name:
Health Quality Ontario
Contact Address:
Evidence Development and Standards, Health Quality Ontario, 130 Bloor Street West, 10th floor, Toronto, Ontario Canada M5S 1N5
Contact Name:
EDSinfo@hqontario.ca
Contact Email:
OH-HQO_hta-reg@ontariohealth.ca
Copyright:
Health Quality Ontario (HQO)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.